This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
Menü
Schließen
Maternal ImmunisationMaternalMaternal Immunisation HomepageSafety ProfileDosingOlder AdultsOlder AdultsOlder Adults HomepageSafety ProfileDosingUseful ResourcesUseful ResourcesVideosMaterialsPreparationPrescribing Information


▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.

Please refer to the ABRYSVO Summary of Product Characteristics for full prescribing information


 Dosing, administration and storage of ABRYSVO for older adults

Please refer to the Summary of Product Characteristics before administering this vaccine.

Reconstitute

  • ABRYSVO must be reconstituted prior to the administration by adding the entire contents of the pre-filled syringe of solvent to the vial containing the powder using the vial adaptor.1
  • The vaccine must be reconstituted only with the solvent provided.1

Posology

  • A single dose of 0.5 mL should be adiministered. 1

Method of administration

  • Abrysvo is for intramuscular injection into the deltoid region of the upper arm. 1
  • The vaccine should not be mixed with any other vaccine or medical products. 1
     

    • Special precautions for storage 

    • Store in a refrigerator (2ºC - 8ºC)1
    • Do not freeze, Discard if the carton has been frozen.1

    • Abrysvo should be administered immediately after reconstitution or within 4 hours if stored between 15°C and 30°C.1

    • Chemical and physical in-use stability has been demonstrated for 4 hours between 15°C and 30°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.1
      Safety Profile - Older Adults


      Learn more about the safety information of ABRYSVO in older adults. 

       Learn moreLoading

      Reference:

      1. ABRYSVO Summary of Product Characteristics.

         

      Legal Category: S1A
      Further information is available upon request

      PP-A1G-IRL-0056 Date of Preparation: September 2024

      Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
       

      Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

      PfizerPro AccountPfizerPro Account

      Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

      Sign in or RegisterRegisterAccountLog out

      This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

       

      This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

       

      Copyright © 2024 Pfizer Limited. All rights reserved.
       

      PP-UNP-IRL-0832. October 2024
      You are now leaving PfizerPro
      You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


      PP-UNP-IRL-0832. October 2024
      You are now leaving PfizerPro
      ​​​​​​​
      ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

      Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
      business which it has provided or reviewed.

      PP-PFE-GBR-3859. November 2021
      ​​​​​​​
      For Healthcare Professionals in the Republic of Ireland *

      The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

      I confirm that I am a healthcare professional* resident in the Republic of Ireland.

      If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

      *The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

      Terms of use

      PP-UNP-IRL-0832. October 2024

      Yes No